Clinical Trial Update: EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This completed Phase 1 trial evaluated EMD 640 744 administered with Montanide ISA 51 VG in subjects with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• EMD 640 744

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED